Literature DB >> 12817523

Tyramine pharmacokinetics and reduced bioavailability with food.

Chad M VanDenBerg1, Lawrence F Blob, Eva M Kemper, Albert J Azzaro.   

Abstract

Tyramine challenge studies have demonstrated that it requires approximately twice the amount of tyramine administered with a meal compared to administration after a fast to elicit the same effect, suggesting a reduction in bioavailability of tyramine when administered with food. The pharmacokinetics of tyramine when administered in a fasted versus a fed state were studied. A single 200-mg dose of tyramine was administered orally to healthy subjects both after an overnight fast and during a meal. Systemic exposure to tyramine was reduced by 53% (p < 0.05), and the maximum concentration of tyramine was reduced by 72% (p < 0.05) when the dose was administered during a meal. Tyramine maximum serum concentration was observed between 20 minutes and 1 hour when the dose was administered after an overnight fast and appeared to be delayed and/or prolonged by administration during a meal. Tyramine oral clearance was 135 +/- 55.4 L/min, maximum observed serum concentration was 37.7 +/- 26.01 ng/mL, and tyramine elimination half-life was 0.533 (range: 0.330-0.668) hours after administration to fasted subjects. Tyramine bioavailability was significantly reduced when administered with a meal compared to after a fast. The results suggest that larger amounts of dietary tyramine will be required to induce a pressor response equivalent to that following encapsulated tyramine administered in the fasted state.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12817523

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  8 in total

Review 1.  The Prescriber's Guide to the MAOI Diet-Thinking Through Tyramine Troubles.

Authors:  Vincent Van den Eynde; Peter Kenneth Gillman; Barry B Blackwell
Journal:  Psychopharmacol Bull       Date:  2022-05-31

2.  Mechanisms of the antilipolytic response of human adipocytes to tyramine, a trace amine present in food.

Authors:  Christian Carpéné; Jean Galitzky; Chloé Belles; Alexia Zakaroff-Girard
Journal:  J Physiol Biochem       Date:  2018-07-23       Impact factor: 4.158

3.  In vitro, in vivo, and clinical studies of tedizolid to assess the potential for peripheral or central monoamine oxidase interactions.

Authors:  S Flanagan; K Bartizal; S L Minassian; E Fang; P Prokocimer
Journal:  Antimicrob Agents Chemother       Date:  2013-04-22       Impact factor: 5.191

4.  High intake of dietary tyramine does not deteriorate glucose handling and does not cause adverse cardiovascular effects in mice.

Authors:  Christian Carpéné; Stéphane Schaak; Céline Guilbeau-Frugier; Josep Mercader; Jeanne Mialet-Perez
Journal:  J Physiol Biochem       Date:  2015-12-03       Impact factor: 4.158

Review 5.  A reassessment of the safety profile of monoamine oxidase inhibitors: elucidating tired old tyramine myths.

Authors:  Peter Kenneth Gillman
Journal:  J Neural Transm (Vienna)       Date:  2018-09-25       Impact factor: 3.575

6.  Highly Variable Pharmacokinetics of Tyramine in Humans and Polymorphisms in OCT1, CYP2D6, and MAO-A.

Authors:  Muhammad Rafehi; Frank Faltraco; Johannes Matthaei; Thomas Prukop; Ole Jensen; Aileen Grytzmann; Felix G Blome; Ralf Günter Berger; Ulrich Krings; Stefan V Vormfelde; Mladen V Tzvetkov; Jürgen Brockmöller
Journal:  Front Pharmacol       Date:  2019-10-30       Impact factor: 5.810

7.  Multiple Direct Effects of the Dietary Protoalkaloid N-Methyltyramine in Human Adipocytes.

Authors:  Christian Carpéné; Pénélope Viana; Jessica Fontaine; Henrik Laurell; Jean-Louis Grolleau
Journal:  Nutrients       Date:  2022-07-29       Impact factor: 6.706

8.  Biogenic amine production by the wine Lactobacillus brevis IOEB 9809 in systems that partially mimic the gastrointestinal tract stress.

Authors:  Pasquale Russo; Pilar Fernández de Palencia; Andrea Romano; María Fernández; Patrick Lucas; Giuseppe Spano; Paloma López
Journal:  BMC Microbiol       Date:  2012-10-31       Impact factor: 3.605

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.